HCA EVP granted 8,067 stock appreciation rights
HCA Healthcare EVP and Chief Clinical Officer Michael S. Cuffe received a grant of 8,067 stock appreciation rights on January 29, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
HCA Healthcare EVP and Chief Clinical Officer Michael S. Cuffe received a grant of 8,067 stock appreciation rights on January 29, 2026. Each right has an exercise price of $482.53 and is settled in HCA common stock.
The stock appreciation rights vest in four equal annual installments beginning on January 29, 2027, and expire on January 29, 2036. Following this grant, Cuffe beneficially owns 8,067 derivative securities directly related to HCA common stock.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Appreciation Right | 8,067 | $0.00 | $0.00 |
Footnotes (1)
- F1. The stock appreciation rights vest in four equal annual installments beginning on January 29, 2027.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did HCA (HCA) EVP Michael Cuffe receive in this Form 4 filing?
When do Michael Cuffe’s HCA stock appreciation rights start vesting?
How many HCA stock appreciation rights does Michael Cuffe hold after this transaction?
What is the exercise price and expiration date of the HCA stock appreciation rights?
How are Michael Cuffe’s HCA stock appreciation rights settled?
Is Michael Cuffe’s ownership in this HCA filing direct or indirect?
AI-generated analysis. How Rhea-AI works. Not financial advice.